Human Monoclonal International is categorized under Medical Research in Los Angeles, CA and active since 1995.
Human Monoclonal International was established in 1995, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Reiko Irie at the company’s single location by writing to 1943 South Westgate Avenue, Los Angeles, California CA 90025 or by phoning (856) 678-6006. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Human Monoclonal International |
| Contact Person: | Reiko Irie |
| Address: | 1943 South Westgate Avenue, Los Angeles, California 90025 |
| Phone Number: | (856) 678-6006 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1995 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Human Monoclonal International was started in 1995 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Reiko Irie for inquiries that concern Human Monoclonal International by calling the company number (856) 678-6006, as your correspondence is most welcome. Additionally, the physical location of the single location of Human Monoclonal International can be found at the coordinates 34.035381,-118.453401 as well as the street address 1943 South Westgate Avenue in Los Angeles, California 90025.
For its online presence, you may visit Human Monoclonal International’s website at and engage with its social media outlets through on Twitter and on Facebook.